INABNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Market cap
$9.636 M
$0.98 +0.90%
Close of 7 Aug 2026
Revenue
—
Not reported
Earnings
-$19.4M
Loss-making
Shares outstanding
9,858,383
Latest filing cover page
P/E ratio
—
Cap ÷ net income
Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap
All 160 →Where these numbers come from
Share counts and financials for In8bio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.